A Population Pharmacokinetic Approach to Understand the Effect of Efavirenz on CYP3A Activity in Healthy Volunteers Using Midazolam as a Probe
CPT: Pharmacometrics & Systems Pharmacology · 2025-12 · 14 (12) · 2095-2106
DOI: 10.1002/psp4.70116 ↗Kurz gefasst
Klinische Studie in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 24.09.2025. Verfasst von Kimberly S Collins und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Benzoxazines, Cytochrome P-450 CYP3A, Midazolam. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Institute of Health/National Institute of General Medical Sciences, NIGMS NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Efavirenz induces and inhibits multiple drug‐metabolizing enzymes, contributing to significant drug–drug interactions. This study quantified the impact of multiple doses of efavirenz on CYP3A activity via midazolam metabolism using a population pharmacokinetic approach. Healthy volunteers received 1 mg midazolam orally in two sessions: first with a single 600 mg efavirenz dose and then after chronic efavirenz dosing (600 mg/day for 17 days). Midazolam and 1′‐hydroxymidazolam were quantified via LC–MS/MS, and CYP2B6, CYP3A4, and CYP3A5 genotypes were assessed using TaqMan assays. Seventy‐two volunteers ( n = 72) completed sampling after the initial dose, and 58 completed both occasions. Non‐linear mixed effects modeling was performed using the stochastic approximation expectation maximization estimation method in NONMEM. The base pharmacokinetic model employed was a two‐compartment model with first‐order absorption and first‐order elimination, incorporating proportional error terms for midazolam and 1′‐hydroxymidazolam. Covariate analysis utilized a full model approach to assess the impact of CYP3A4 and CYP3A5 genotypes, self‐reported sex, and multiple doses of efavirenz as covariates affecting the formation clearance of 1‐OH midazolam. CYP3A5 expressors exhibited a 1.27‐fold increase in midazolam clearance compared to non‐expressors, while CYP3A4 intermediate metabolizers showed a 0.94‐fold decrease relative to normal metabolizers. Clearance was also 1.30‐fold higher in females compared to males. Multiple doses of efavirenz increased midazolam clearance by 1.92‐fold (95% CI 1.65–2.28) after accounting for inter‐individual variability caused by other covariates. Furthermore, K a and bioavailability ( F ) increased with repeated efavirenz exposure. In conclusion, this population pharmacokinetic analysis effectively quantified the specific induction effect of multiple doses of efavirenz on CYP3A compared to a single dose of efavirenz. Trial Registration: ClinicalTrials.gov identifier: NCT00668395
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Quantitative Medicine, Critical Path Institute, Tucson, Arizona, USA.
- Department of Pharmacology and Clinical Pharmacology, Christian Medical College, Vellore, India.
- Department of Pharmacy, Faculty of Health Sciences, Universidade de Brasília, Brasília, Brazil.
- Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
ORCID-Profile: Kimberly S Collins, Blessed W Aruldhas, Ingrid F Metzger, Michael A Heathman, Sara K Quinney, Zeruesenay Desta
Förderung
- National Institute of Health/National Institute of General Medical Sciences
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Collins, K. S., Aruldhas, B. W., Metzger, I. F., Lu, J. B. L., Heathman, M. A., Quinney, S. K., & Desta, Z. (2025). A Population Pharmacokinetic Approach to Understand the Effect of Efavirenz on CYP3A Activity in Healthy Volunteers Using Midazolam as a Probe. CPT: Pharmacometrics & Systems Pharmacology, 14(12), 2095-2106. https://doi.org/10.1002/psp4.70116
Vancouver
Collins KS, Aruldhas BW, Metzger IF, Lu JBL, Heathman MA, Quinney SK, et al. A Population Pharmacokinetic Approach to Understand the Effect of Efavirenz on CYP3A Activity in Healthy Volunteers Using Midazolam as a Probe. CPT: Pharmacometrics & Systems Pharmacology. 2025;14(12):2095-2106. doi:10.1002/psp4.70116
BibTeX
@article{Collins2025,
author = {Collins, Kimberly S and Aruldhas, Blessed W and Metzger, Ingrid F and Lu, Jessica B L and Heathman, Michael A and Quinney, Sara K and Desta, Zeruesenay},
title = {A Population Pharmacokinetic Approach to Understand the Effect of Efavirenz on CYP3A Activity in Healthy Volunteers Using Midazolam as a Probe},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
volume = {14},
number = {12},
pages = {2095--2106},
doi = {10.1002/psp4.70116}
}
EUVIMED